Immunometabolism Modulation in Therapy

Ezequiel Monferrer; Sabina Sanegre; Isaac Vieco-Martí; Amparo López-Carrasco; Fernando Fariñas; Antonio Villatoro; Sergio Abanades; Santos Mañes; Luis de la Cruz-Merino; Rosa Noguera; Tomás Álvaro Naranjo

doi:10.3390/biomedicines9070798

Biomedicines (Jul 2021)

Immunometabolism Modulation in Therapy

Ezequiel Monferrer,
Sabina Sanegre,
Isaac Vieco-Martí,
Amparo López-Carrasco,
Fernando Fariñas,
Antonio Villatoro,
Sergio Abanades,
Santos Mañes,
Luis de la Cruz-Merino,
Rosa Noguera,
Tomás Álvaro Naranjo

Affiliations

Ezequiel Monferrer: Department of Pathology, Medical School, University of Valencia–INCLIVA Biomedical Health Research Institute, 46010 Valencia, Spain
Sabina Sanegre: Department of Pathology, Medical School, University of Valencia–INCLIVA Biomedical Health Research Institute, 46010 Valencia, Spain
Isaac Vieco-Martí: Department of Pathology, Medical School, University of Valencia–INCLIVA Biomedical Health Research Institute, 46010 Valencia, Spain
Amparo López-Carrasco: Department of Pathology, Medical School, University of Valencia–INCLIVA Biomedical Health Research Institute, 46010 Valencia, Spain
Fernando Fariñas: Ynmun Group, Institute of Clinical Immunology and Infectious Diseases, 290015 Málaga, Spain
Antonio Villatoro: Ynmun Group, Institute of Clinical Immunology and Cell Therapy (IMMUNESTEM), 29018 Málaga, Spain
Sergio Abanades: Integrative and Conscious Health Institute, 08008 Barcelona, Spain
Santos Mañes: Centro Nacional de Biotecnología (CNB/CSIC), Department of Immunology and Oncology, 28015 Madrid, Spain
Luis de la Cruz-Merino: Clinical Oncology Department, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain
Rosa Noguera: Department of Pathology, Medical School, University of Valencia–INCLIVA Biomedical Health Research Institute, 46010 Valencia, Spain
Tomás Álvaro Naranjo: Low Prevalenc Tumors, Centro de Investigación Biomédica En Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain

DOI: https://doi.org/10.3390/biomedicines9070798
Journal volume & issue: Vol. 9, no. 7
p. 798

Abstract

Read online

The study of cancer biology should be based around a comprehensive vision of the entire tumor ecosystem, considering the functional, bioenergetic and metabolic state of tumor cells and those of their microenvironment, and placing particular importance on immune system cells. Enhanced understanding of the molecular bases that give rise to alterations of pathways related to tumor development can open up new therapeutic intervention opportunities, such as metabolic regulation applied to immunotherapy. This review outlines the role of various oncometabolites and immunometabolites, such as TCA intermediates, in shaping pro/anti-inflammatory activity of immune cells such as MDSCs, T lymphocytes, TAMs and DCs in cancer. We also discuss the extraordinary plasticity of the immune response and its implication in immunotherapy efficacy, and highlight different therapeutic intervention possibilities based on controlling the balanced systems of specific metabolites with antagonistic functions.

Published in Biomedicines

ISSN: 2227-9059 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Biology (General)
Website: http://www.mdpi.com/journal/biomedicines

About the journal

Abstract

Keywords